Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells (Q40554546)

21 September 2017

title

Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells (English)

1 reference

21 September 2017

Brandi R Whitley

1

1 reference

21 September 2017

Diane Palmieri

series ordinal

2

1 reference

21 September 2017

Christine D Twerdi

series ordinal

3

1 reference

21 September 2017

Frank C Church

series ordinal

4

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

Experimental Cell Research

21 September 2017

published in

1 reference

21 September 2017

volume

296

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

151-162

1 reference

The fibrinolytic system in neoplasia

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

The plasminogen activation system in tumor growth, invasion, and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Plasminogen Activator Inhibitor Type 2 Inhibits Tumor Necrosis Factor α-induced Apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Assessment of the interaction between urokinase and reactive site mutants of protein C inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Two distinct urokinase-serpin interactions regulate the initiation of cell surface-associated plasminogen activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Plasminogen activator inhibitors in endometrial adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Plasminogen activator inhibitor type 2 in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

A simplified system for generating recombinant adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Matrix metalloproteinase expression in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Insulin-like growth factor-binding protein 1 stimulates human trophoblast migration by signaling through alpha 5 beta 1 integrin via mitogen-activated protein Kinase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Dissemination risk index based on plasminogen activator system components in primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.02.022

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YEXCR.2004.02.022

1 reference

21 September 2017

1 reference